News

About half of cystic fibrosis (CF) patients had used, were using, or were interested in using cannabidiol (CBD), the main active compounds found in the cannabis plant, according to a new survey and analysis conducted at a U.S. center. “Cannabidiol is used to treat a variety of symptoms including…

More severe lung disease and using inhaled corticosteroids are associated with shorter telomere length, a sign of cellular aging, in immune cells from people with cystic fibrosis (CF), a study suggests. Telomeres are stretches of repetitive DNA that protect the ends of chromosomes, the long strings of DNA that…

Most people with cystic fibrosis (CF) who carry mutations that make them ineligible for CFTR modulators are prescribed medications that improve mucus thinning and clearance. Antibiotic use is also high, and because most patients had pancreatic insufficiency, treatment with pancreatic enzyme replacement therapy is also common. That’s according…

Having COVID-19 had no clinically meaningful impact on lung function and nutritional status for people with cystic fibrosis in the year after an infection, a study across 33 countries indicates. According to the researchers, the “study is [a] global representation of the impact of COVID-19 on the health of…

Claire’s Place Foundation is gearing up to celebrate its 10th Annual Glow Ride for Cystic Fibrosis (CF) that’s set to happen Sept. 21 at Hermosa Beach, California. The milestone event aims to raise crucial funds to…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) cut sweat chloride levels in half among people with cystic fibrosis (CF), according to a real-world Danish study. Still, sweat chloride levels — a known biomarker of treatment responses in CF — were variable, and some treated patients still had levels out of the…

The Rare Disease Cures Accelerator-Data and Analytics Platform — dubbed RDCA–DAP — has received new datasets that promise to accelerate research and the development of new therapies for cystic fibrosis (CF). The data was generated by the Cystic Fibrosis Therapeutics Development Network (TDN), known for its clinical trials…

An infant boy, who was first seen with recurrent infections and a failure to thrive, was diagnosed with cystic fibrosis (CF) caused by a rare genetic mutation, a case study reports. “This case underscores the importance of considering CF even when classic symptoms are absent, as genetic mutation can…

A 3-year-old boy who carries a new combination of two mutations in the CFTR gene, but with no clinical signs of cystic fibrosis (CF), was described by researchers in a case report. “The case presented has no clinical symptoms so far and doesn’t meet the criteria for a…

The U.S. Food and Drug Administration (FDA) has cleared a Phase 2 clinical trial testing ARCT-032, an inhaled therapy candidate, in people with cystic fibrosis (CF). Arcturus Therapeutics, the therapy’s developer, did not announce when the trial is expected to start. “The study is designed to evaluate the…